Perfuze is developing clot removal, medical device technology, the Millipede Clot Ingestion System (CIS) to treat Acute Ischemic Stroke.
Acute Ischemic Stroke (AIS) Stroke is a devastating disease, it is the No. 2 cause of death and the leading cause of adult physical disability. Globally, 17 million people had a stroke in 2019. Of these, 33% died and 33% were permanently disabled. A stroke occurs when an artery in the brain is blocked by a clot, preventing blood flow, restricting oxygen and nutrients and inducing brain damage.
The clinical and economic burden on health providers is enormous. In 2018, in the EU and US, the direct and indirect healthcare cost of stroke was estimated at greater than €100 billion. Between 2012 and 2030, total direct medical stroke-related costs are projected to triple. Among patients discharged from the hospital after stroke, 30% are discharged to long-term nursing facilities.
These mediocre outcomes are no longer acceptable.
The critical metric for assessing a positive clinical outcome post treatment is complete reperfusion i.e. complete extraction of the clot from the brain. Today, complete reperfusion is achieved on the first attempt in approximately 31% patients. To improve clinical outcomes the physician requires tools that enable the entire clot to be removed from the brain in a single pass. Perfuze has designed technology that can increase this number significantly, our testing to date indicates that we achieve this in up to 90% of cases.
The overall objective of the H2020 project is : 1)validate the technology in a First-In-Human clinical study 2) prepare the company for EU commercialisation and scale, and 3) secure US regulatory approval for a large clinical trial.
Our vision is to completely reperfuse (restore blood-flow) the brain in order to dramatically improve outcomes, and reduce healthcare costs.
